Home > Resources > Whitepapers > Incentive Compensation Management: Build Versus Buy

Incentive Compensation Management: Build Versus Buy

July 23, 2018

Custom ICM solutions are built for you, not auditors, so they typically don’t offer visibility into actions performed over time. Auditors may lack confidence in your homegrown system, especially if they find errors or omissions. In fact, audit risk from errors and overpayments is often the most compelling reason we see customers switch from build to buy. New regulations place additional burdens on your commissions system.

I'm For Real

Enter your details once to access all our information and resources

Spotlight

CELENYS

CELENYS is a biotechnology company specialized in development and sale of innovative hyaluronic acid based scaffolds for 3D cell culture. CELENYS develops 3D in vitro study models to come closer to in vivo systems by mimicking the cellular microenvironment. Applications are screening of compounds during drug development (toxicology, ADME, discovery…) on 3D cell cultures and mechanistic research.

OTHER WHITEPAPERS
news image

Next Generation Therapies and related Life Sciences topics

whitePaper | January 16, 2022

All gene therapies insert engineered DNA/RNA into living cells to make or modify new proteins

Read More
news image

The US Bioeconomy

whitePaper | April 14, 2022

In the nearly 50 years since the first genetic engineering experiments, the United States has become the world’s biotechnology powerhouse,

Read More
news image

Lipid Nanoparticle and Liposome

whitePaper | September 12, 2022

Lipid nanoparticles (LNPs) and liposomes are variations of lipid-based drug carriers differing in their internal structure.

Read More
news image

Covid-19 Vaccine Distribution System

whitePaper | April 14, 2021

Delivering Covid-19 vaccines to 7.8 billion people is a daunting challenge that will stretch supply chains past their limits. Even if all the needed doses were ready today, vaccine manufacturers still must find solutions to deliver multiple doses of those vaccines to most people on the planet. To read more, please download this free white paper.

Read More
news image

Cell and Gene Therapy Hot Buttons Series

whitePaper | September 27, 2022

Cell and Gene Therapy (CAGT) activity has increased dramatically in recent decades, especially in Chimeric Antigen Receptor T-Cell (CAR-T) clinical trials and therapy registrations. The IQVIA CAGT Hot Buttons series covers basic concepts in CAGT for newcomers to this field.

Read More
news image

Optimizing Freeze-Thaw Processes for Cell and Gene Therapy Commercialization

whitePaper | June 23, 2022

Cell and gene therapies require both efficient and reliable freeze-thaw systems. Building the most effective system depends on selecting the right materials and instruments.

Read More

Next Generation Therapies and related Life Sciences topics

whitePaper | January 16, 2022

All gene therapies insert engineered DNA/RNA into living cells to make or modify new proteins

Read More

The US Bioeconomy

whitePaper | April 14, 2022

In the nearly 50 years since the first genetic engineering experiments, the United States has become the world’s biotechnology powerhouse,

Read More

Lipid Nanoparticle and Liposome

whitePaper | September 12, 2022

Lipid nanoparticles (LNPs) and liposomes are variations of lipid-based drug carriers differing in their internal structure.

Read More

Covid-19 Vaccine Distribution System

whitePaper | April 14, 2021

Delivering Covid-19 vaccines to 7.8 billion people is a daunting challenge that will stretch supply chains past their limits. Even if all the needed doses were ready today, vaccine manufacturers still must find solutions to deliver multiple doses of those vaccines to most people on the planet. To read more, please download this free white paper.

Read More

Cell and Gene Therapy Hot Buttons Series

whitePaper | September 27, 2022

Cell and Gene Therapy (CAGT) activity has increased dramatically in recent decades, especially in Chimeric Antigen Receptor T-Cell (CAR-T) clinical trials and therapy registrations. The IQVIA CAGT Hot Buttons series covers basic concepts in CAGT for newcomers to this field.

Read More

Optimizing Freeze-Thaw Processes for Cell and Gene Therapy Commercialization

whitePaper | June 23, 2022

Cell and gene therapies require both efficient and reliable freeze-thaw systems. Building the most effective system depends on selecting the right materials and instruments.

Read More
More Whitepapers

Spotlight

CELENYS

CELENYS is a biotechnology company specialized in development and sale of innovative hyaluronic acid based scaffolds for 3D cell culture. CELENYS develops 3D in vitro study models to come closer to in vivo systems by mimicking the cellular microenvironment. Applications are screening of compounds during drug development (toxicology, ADME, discovery…) on 3D cell cultures and mechanistic research.

Events